M.D. Sass Concentrated Value ETF
SASS - ETF AI Analysis
Top Page
M.D. Sass Concentrated Value ETF (SASS)
SASS (M.D. Sass Concentrated Value ETF) has a solid overall rating, largely supported by strong holdings like Quest Diagnostics, Clean Harbors, and Welltower, which show robust financial performance, positive market trends, and encouraging earnings commentary. Amazon, Capital One, Ares, and others also add strength through growth and strategic initiatives, though several holdings share a common concern of high valuations. A key risk is that many top positions appear richly priced or face specific operational challenges (such as Primo Brands’ profitability issues), which could limit upside if market conditions weaken.
SASS vs. SPDR S&P 500 ETF (SPY)
- AUM
- 78.81M
- Region
- North America
- Expense Ratio
- 0.75%
- Beta
- 0.62
- Issuer
- M.D. Sass
- Inception Date
- Mar 04, 2026
- Dividend Yield
- N/A
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
SASS Summary
M.D. Sass Concentrated Value ETF (SASS) is an actively managed fund that focuses on U.S. companies the manager believes are undervalued, following a value investing theme rather than a specific index. It holds a small, focused list of large and mid-sized stocks across many sectors, including well-known names like Amazon and Capital One Financial. Investors might consider SASS if they want a concentrated, value-tilted fund that aims for long-term growth and diversification beyond broad market index ETFs. A key risk is that its focused portfolio can move up or down more sharply than the overall market, especially if the manager’s stock picks don’t perform as expected.
How much will it cost me?
This ETF has an expense ratio of 0.75%, which means you’ll pay about $7.50 per year for every $1,000 you invest. That’s higher than the average ETF because it’s actively managed, paying a professional team to research and select a smaller group of value stocks they believe can outperform the market.
What would affect this ETF?
This ETF could benefit if the U.S. economy stays healthy, industrial and health care companies grow profits, and investors favor value stocks, which may help its concentrated bets in names like Ametek, Henry Schein, and Amazon. On the other hand, a U.S. slowdown, rising interest rates hurting financials and real estate, or poor performance from a few large holdings could weigh heavily on returns because the fund is focused in specific sectors and a relatively small number of stocks.
SASS Top 10 Holdings
This is a true stock‑picker’s value fund, with performance hinging on a handful of U.S. names rather than any one sector. Quest Diagnostics and Welltower are doing the heavy lifting, with steady, rising trends that fit the fund’s focus on stable cash flows. Primo Brands and StandardAero add some punch but with bumpier, mixed results, while Amazon looks a bit tired lately and isn’t the classic value engine here. Financials like Capital One and Ares have been lagging, acting as a mild brake on overall returns.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 AMZN | Amazon | 6.88% | $5.47M | $2.93T | 6.85% | 71Outperform |
 PRMB | Primo Brands | 6.83% | $5.43M | $8.70B | 55.14% | 57Neutral |
 COF | Capital One Financial | 5.56% | $4.42M | $117.80B | -10.71% | 71Outperform |
 ARES | Ares Management | 5.32% | $4.23M | $46.02B | -10.39% | 70Outperform |
 KNX | Knight Transportation | 5.25% | $4.17M | $10.11B | 40.71% | 64Neutral |
 SARO | StandardAero, Inc. | 5.22% | $4.15M | $9.35B | 5.39% | 67Neutral |
 DGX | Quest Diagnostics | 5.12% | $4.07M | $28.43B | 36.98% | 79Outperform |
 WELL | Welltower | 4.98% | $3.96M | $181.69B | 28.62% | 77Outperform |
 FLS | Flowserve | 4.89% | $3.89M | $10.86B | 22.80% | 79Outperform |
 AME | Ametek | 4.78% | $3.80M | $54.65B | 21.28% | 79Outperform |
SASS Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For SASS, the sentiment is Positive. The current price of 24.69 is above the 20-day moving average (MA) of 23.80, above the 50-day MA of 23.81, and compared to the 200-day MA of , indicating a neutral trend. The MACD of 0.18 indicates Negative momentum. The RSI at 61.64 is Neutral, neither overbought nor oversold. The STOCH value of 91.06 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SASS.
SASS Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| SASS | $24.69 | $25.00(1.26% Upside) | $78.81M | 0.75% | 64Neutral |
 BAMD | $34.31 | $38.05(10.89% Upside) | $98.69M | 0.87% | 71Outperform |
 VUSV | $73.65 | $84.85(15.21% Upside) | $94.11M | 0.30% | 68Neutral |
 CVAR | $32.51 | $35.04(7.77% Upside) | $47.78M | 0.87% | 57Neutral |
 GVLE | $49.64 | $56.36(13.54% Upside) | $41.31M | 0.45% | 69Neutral |
 USFE | $37.91 | $43.96(15.95% Upside) | $4.91M | 0.45% | 70Outperform |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SASS | M.D. Sass Concentrated Value ETF | 24.69 | -0.42 | -1.68% | |
| BAMD | Brookstone Dividend Stock ETF | 34.31 | 5.15 | 17.65% | |
| VUSV | Vanguard Wellington U.S. Value Active ETF | 73.65 | 14.26 | 24.01% | |
| CVAR | Cultivar ETF | 32.51 | 5.17 | 18.92% | |
| GVLE | Goldman Sachs Value Opportunities ETF | 49.64 | 10.54 | 26.96% | |
| USFE | First Eagle US Equity ETF | 37.91 | 3.03 | 8.68% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.